On October 30, 2023, the Department of Justice announced that Nostrum Laboratories Inc. and its CEO “agreed to pay a minimum of $3,825,000, and up to $50 million if certain financial contingencies are met,” to resolve False Claims Act allegations associated with Medicaid rebates for a drug calledNitro OS. After acquiring and relaunching Nitro OS in August 2018, Nostrum increased the drug’s price from $474.75 to $2,392.32 per bottle– triggering significantly higher Medicaid Drug Rebate invoices from State Medicaid programs– but allegedly did not pay the entire invoiced amounts.